AUTHORS
Hanny Al-Samkari, MD, Marie E. Faughnan, MD MSc2, Vivek Iyer, M.D.3, Magdalena Lewandowska, MD4, Adrienne Hammill, MD PhD5, Jenny Y Zhou, MD6, Marcelo Serra, MD7, Guido Manfredi, MD PhD8, Quentin Van Thillo, MD9, Sonia S Thomas, DrPh10, Sebastien Ronseaux, Ph.D.11, Christopher F Bennett, Ph.D.12, Lori Steelman, MS13, Patrick McNamara, MS14, Shuchi Pandya, MD15, Sophie Dupuis-Girod, MD PhD16, Raj Kasthuri, MBBS17
AFFILIATIONS
1 Mass General Brigham Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
2 Li Ka Shing Knowledge Institute, Unity Health Toronto - St. Michael's Hospital, Toronto, Canada
3 Mayo Clinic, Rochester, Minnesota, United States
4 Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, United States
5 Cincinnati Children's Hospital, Cincinnati, Ohio, United States, University of Cincinnati College of Medicine, Cincinnati, Ohio, United States
6 University of California - San Diego, San Diego, California, United States
7 Hospital Italiano, Buenos Aires, Argentina
8 HHT European Reference Center, ASST Crema, Crema, Italy
9 UZ Leuven, Leuven, Belgium
10 Atavistik Bio, Cambridge, Massachusetts, United States
11 Atavistik Bio, Cambridge, Massachusetts, United States
12 Atavistik Bio, Cambridge, Massachusetts, United States
13 Atavistik Bio, Cambridge, Massachusetts, United States
14 Atavistik Bio, Cambridge, Massachusetts, United States
15 Atavistik Bio, Cambridge, Massachusetts, United States
16 Hospices Civils de Lyon, National HHT Reference Center. Femme-Mere-Enfant Hospital, Bron, France
17 University of North Carolina, Chapel Hill, North Carolina, United States
ABSTRACT
Background and Significance: HHT is the second most common inherited bleeding disorder affecting approximately 1.6 million people worldwide (Faughnan et al., Ann. Intern. Med. 2020). HHT is associated with significant morbidity and may be the most morbid inherited bleeding disorder in women (Zhang et al., Blood Adv. 2024). HHT is characterized by the development of telangiectasias and arteriovenous malformations (AVMs) that lead to epistaxis and other sources of chronic bleeding in addition to organ dysfunction. There are no approved therapies for HHT, but AKT inhibition has emerged as a promising therapeutic approach in HHT (Al-Samkari et al., New Eng J Med 2025). AKT1 is the predominant AKT isoform in endothelial cells and is overactivated in HHT, driving dysregulated angiogenesis and telangiectasia/AVM formation. ATV-1601 is a novel orally bioavailable allosteric AKT1 inhibitor with approximately 10-fold selectivity of AKT1 over AKT2 (a different isoform involved in insulin-stimulated glucose uptake and homeostasis). This selectivity may allow for a more favorable safety profile while preserving efficacy. ATV-1601 was previously studied in a dose escalation study in patients with advanced solid tumors and was generally well tolerated with no dose-limiting toxicities or treatment discontinuations due to adverse events. The preliminary tolerability, pharmacokinetic profile and evidence of target engagement via AKT1 phosphorylation supported the ATV-1601 dose selection for evaluation in HHT. AT-867, an advanced compound and analog of ATV-1601 with a similar pharmacological profile, prevented the formation of retinal AVMs, rescued pathological angiogenesis, and normalized hyperactive AKT1 signaling in preclinical neonate and adult mouse HHT models.
Study Design and Methods: Harmony-HHT (NCT06701425) is a global, randomized, double-blind, placebo-controlled Phase 1/2 study evaluating the safety and efficacy of 3 dose regimens of ATV-1601 in adults with HHT and moderate-to-severe HHT-associated epistaxis. All doses of ATV-1601 are projected to achieve continuous >50% AKT1 target engagement. Key eligibility criteria include ≥18 years of age with genetic or clinical HHT diagnosis per Curaçao criteria; Epistaxis Severity Score ≥4; ≥20 episodes and ≥80 minutes (cumulative) of epistaxis duration over a 28-day observation period collected via participant electronic daily diary; anemia based on screening hemoglobin, and/or requirement for packed red cell transfusion or intravenous iron; and no prior AKT inhibitor treatment. Approximately 100 eligible participants will be randomized 1:1:1:1 to receive blinded ATV-1601 60 mg daily (QD), 100 mg daily (QD) or 60 mg twice daily (BID) or matching placebo for 16 weeks in Part 1. Participants who complete Part 1 can receive ATV-1601 for up to 2 years in an open-label extension (Part 2). An independent data monitoring committee (IDMC) has been appointed to monitor the conduct and data from this ongoing study.
Primary study endpoints include incidence and severity of treatment-emergent adverse events, determination of recommended Phase 2 dose (Part 1), and long-term safety and tolerability of ATV-1601 (Part 2). Secondary endpoints include changes from baseline in epistaxis frequency, duration, intensity, and intensity-weighted duration based on data collected using participant daily diary; changes in Epistaxis Severity Score, hemoglobin, iron infusions, and red blood cell transfusions; and pharmacokinetics. Exploratory endpoints include changes in composite hematologic endpoints, the Hematologic Support Score and Hematologic Impact Score; HHT-specific Quality of Life; Menstrual Bleeding Questionnaire in menstruating women; and changes in hemodynamic parameters, such as right to left pulmonary shunting and hepatic flow in participants with lung and liver AVMs, respectively.
Study Status: ATV-1601 is a novel investigational AKT1-selective oral inhibitor with potential to reduce bleeding and have a disease modifying effect in HHT. The Harmony-HHT study is actively recruiting.
DISCLOSURES
Hanny Al-Samkari, MD: Atavistik - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; SOBI - Research Funding; Novartis - Research Funding; Alnylam - Research Funding; Vaderis - Research Funding; Tectonic - Research Funding; Argenx - Research Funding; Agios Pharmaceuticals - Research Funding; Alpine Immune Sciences - Research Funding; Pharmacosmos - Research Funding; Novartis - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Tectonic - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Diagonal - Consultancy (Includes expert testimony); Terremoto - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Atavistik - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)